Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Vivek Ramaswamy

Roivant Sciences Ltd.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

Metric
Company Name	Roivant Sciences Ltd.
Symbol	ROIV
MSH ID	COM:ROIVANT
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	GB
Stage
Employee Count	908
Website	roivant.com
LinkedIn	roivant-sciences-inc-
Founders

Metric
Market Cap	8.31B
Enterprise Value
Monthly Web Traffic	13.29K
Web Traffic Growth	-0.61
Valuation
Raised Capital

Metric
Revenue	124.80M
Revenue (LTM)
Revenue (NTM)
Gross Profit	109.23M
EBITDA	-996.51M
Operating Income	4.24B
Net Income	4.35B
EPS	5.55
Diluted EPS	5.23
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.89
Operating Profit Margin	39.17
EBITDA Margin	-7.99
Net Profit Margin	35.09
Return on Equity	1.81
Return on Assets	0.73
Return on Capital Employed	0.77

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

11.82

22/11 21:00

Market Cap

8.31B

Beta: -

Volume Today

11.36M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.66
P/B Ratio	8.12
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	75.82
EV Multiple	-13.60

Metric
Days Sales Outstanding	193.28
Days Payables Outstanding	1.06K
Days Inventory Outstanding	826.90
Operating Cycle	1.19K
Cash Conversion Cycle	624.07
Asset Turnover	0.02

Metric
Operating Cash Flow	-765.27M
Free Cash Flow	-766.65M
Cash Flow to Debt	-1.53
Operating Cash Flow/Sales	-4.47
Free Cash Flow Yield	-0.11

Metric
Cash & Equivalents	6.54B
Accounts Receivable
Inventory	35.25M
Goodwill
Debt to Capitalization	0.08
Debt to Assets	0.24
Current Ratio	5.84
Quick Ratio	27.75

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	1.76
R&D to Revenue	4.99
SG&A to Revenue	2.85